| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
TCS-2002 targets glycogen synthase kinase-3β (GSK-3β), a serine/threonine protein kinase that plays a critical role in multiple cellular processes, including glycogen metabolism, cell cycle regulation, and neuronal function. It is a potent inhibitor of GSK-3β with an IC50 of 35 nM. By inhibiting GSK-3β, TCS-2002 modulates tau phosphorylation and other downstream signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, TCS-2002 is a potent inhibitor of GSK-3β with an IC50 of 35 nM. It inhibits GSK-3β activity in cell-based assays. The compound's ability to inhibit GSK-3β makes it a valuable tool for studying the role of this kinase in various diseases, including Alzheimer's disease, diabetes, and cancer. Specific details on assay conditions are not extensively provided.
|
| ln Vivo |
TCS2002 (compound 9b) had favorable pharmacokinetic properties and strong BBB permeability in GS rats and C57BL/6N mice. Its AUC0-24h values were 734 ng·h/g, and its Kp value, or ratio of brain to plasma, was 1.6[1].
In vivo, TCS-2002 has favorable pharmacokinetic properties and strong blood-brain barrier permeability in rats and mice. Oral administration of TCS-2002 inhibits cold water stress-induced tau hyperphosphorylation in the mouse brain. This demonstrates the compound's ability to engage its target in the central nervous system after oral administration. |
| Enzyme Assay |
In vitro kinase assays for TCS-2002 involve measuring GSK-3β activity. Recombinant GSK-3β kinase is incubated with peptide substrates and ATP in the presence of varying concentrations of TCS-2002. Kinase activity is quantified by measuring phosphorylation of the substrate. IC50 values are calculated from concentration-response curves.
|
| Cell Assay |
For in vitro cell-based assays, cells are cultured and treated with TCS-2002 at various concentrations. GSK-3β activity is assessed by measuring phosphorylation of its downstream targets (e.g., tau, β-catenin) by Western blot. Cell viability is assessed using MTT or similar assays. The compound's effects on glycogen metabolism and cell cycle progression can also be studied.
|
| Animal Protocol |
Animal/Disease Models: IGS rat (male, 8 weeks old) [1]
Doses: 1 and 3 mg/kg Route of Administration: intravenous (iv) (iv)injection and oral administration; continuous for 1, 2, 4, 8, and 24 hrs (hrs (hours)). Experimental Results: 1.19 comp (S)-9b (S)-9c VDSS,iv (mL/kg) 1134 1650 CLtotal,iv (mL/min/kg) 27.4 28.4 Cmax,po (ng/mL) 396.9 289.6 AUC0-24 h ,po (ng·h/mL) 1380.6 1229.1 MRTpo (h) 2.19 3.03 Fd (%) 72.8 65.5 In vivo animal studies for TCS-2002 use rodent models to assess GSK-3β inhibition. The compound is administered orally at doses determined from pharmacokinetic studies. Tau phosphorylation is measured in brain tissues by Western blot. Pharmacokinetic parameters, including AUC and brain-to-plasma ratio (Kp), are measured to assess blood-brain barrier permeability. |
| ADME/Pharmacokinetics |
TCS-2002 has a molecular formula of C18H14N2O3S and a molecular weight of 338.38. It has favorable pharmacokinetic properties and strong blood-brain barrier permeability in rats and mice, with an AUC0-24h of 734 ng·h/g and a brain-to-plasma ratio (Kp) of 1.6. The compound is for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for TCS-2002 are not extensively provided in the available literature. As a GSK-3β inhibitor, it would be expected to have a safety profile related to modulation of this kinase. The compound is for research use only and is not for human or clinical use. Standard toxicology assessments would be required for therapeutic development.
|
| References | |
| Additional Infomation |
TCS-2002 is a potent and cell-permeable inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 of 35 nM. It has favorable pharmacokinetic properties and strong blood-brain barrier permeability. Oral administration inhibits cold water stress-induced tau hyperphosphorylation in the mouse brain. The compound is used as a research tool to study the role of GSK-3β in Alzheimer's disease and other conditions. No approved therapeutic status is reported.
|
| Molecular Formula |
C18H14N2O3S
|
|---|---|
| Molecular Weight |
338.381
|
| Exact Mass |
338.073
|
| CAS # |
1005201-24-0
|
| PubChem CID |
24855958
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.061
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
469
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RCKYSTKYIVULEK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H14N2O3S/c1-11-19-20-18(23-11)13-5-8-17-15(9-13)16(10-22-17)12-3-6-14(7-4-12)24(2)21/h3-10H,1-2H3
|
| Chemical Name |
2-methyl-5-[3-(4-methylsulfinylphenyl)-1-benzofuran-5-yl]-1,3,4-oxadiazole
|
| Synonyms |
TCS2002; TCS 2002; TCS-2002
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9553 mL | 14.7763 mL | 29.5526 mL | |
| 5 mM | 0.5911 mL | 2.9553 mL | 5.9105 mL | |
| 10 mM | 0.2955 mL | 1.4776 mL | 2.9553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
